Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial

Older patients with ALL are often intolerant to intensive chemotherapy and have poor outcomes. We hypothesized that combination of low-intensity chemotherapy with anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (InO) may improve outcomes in the frontline setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research